Ravi Venkatesan, the Chairman of Microsoft India from 2004-2011, who helped build and expand Microsoft's largest presence outside of the USA in India, has joined the Boards of Strand Life Sciences, a new generation healthcare innovation company headquartered in Bangalore, and its US subsidiary, Strand Genomics, Inc.
Venkatesan is the author of the acclaimed "Conquering the Chaos: Win in India, Win Everywhere" published by HBR and currently the founder chairman of the Social Ventures Partners, India and serves as a director on the Boards of Infosys and AB Volvo.
Mr. Venkatesan has held multiple senior leadership positions. He served as the Chairman of Microsoft India from 2004-2011, and as the Chairman of Cummins India. He holds a BS in engineering from IIT Bombay, MS from Purdue University, and an MBA from Harvard Business School where he was a Baker Scholar. He was voted as the most influential MNC CEO by the Economic Times in 2011. He was also voted as one of India's best management thought leaders by Thinkers50.
"The advances in genomics are greatly complemented by those of computer science," said Ravi Venkatesan. "The future of cancer screening, diagnostics, and screening for genetic predispositions is being transformed by the melding of the two fields, and Strand Life Sciences is among the world leaders in this important transformative arena."
Commenting on his joining Strand's Board, Mr. Venkatesan, mentioned, "It is my pleasure to join the innovation leader in personalized medicine using genomics. In the past year, Strand has begun to commercialize its software platform and testing services for clinical use. It will play an increasingly important role going forward for India and the rest of the world."
Commenting on Mr. Venkatesan's joining the Board, Dr. Vijay Chandru, Chairman and CEO of Strand said, "We are delighted to have Ravi Venkatesan on board especially at a crucial junction when the company has strategized for exponential growth in the individualized medicine space. Ravi brings a wealth of experience that facilitates the company's growth as a global leader in clinical genomics."